SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced breakthrough software advancements for its sequencing platform that enable real time analysis and provide a significant reduction in computing infrastructure requirements. These software improvements, in combination with the new Genome AnalyzerIIx, enable researchers to increase their sequencing output up to 65% relative to the Genome AnalyzerII. Breaking from the industry trend, where increased data output requires increased computing power and infrastructure, Illumina is simplifying computing and data processing by enabling base calling and quality assessment on the instrument control workstation.
